Beacon Roofing Supply Inc
NASDAQ:BECN

Watchlist Manager
Beacon Roofing Supply Inc Logo
Beacon Roofing Supply Inc
NASDAQ:BECN
Watchlist
Price: 118.34 USD 0.31% Market Closed
Market Cap: 7.3B USD

Beacon Roofing Supply Inc
Investor Relations

Beacon Roofing Supply Inc. stands as a formidable pillar in North America's building materials landscape. Established in 1928, the company has steadily evolved into one of the largest distributors of roofing products and complementary building materials in the region. Its operations are a well-oiled machine, with a vast network of over 400 locations strategically positioned across the United States and Canada. This extensive footprint allows the company to effectively serve a diverse client base that includes roofing contractors, builders, and remodelers. The heart of Beacon's business lies in its adept handling of logistics and supply chain management, ensuring prompt and reliable delivery of its offerings, which range from residential and commercial roofing products to an array of siding, insulation, and waterproofing solutions.

Beacon's journey through the market is steered by its commitment to quality and customer service, driving its profitability engine. The company leverages its scale to negotiate favorable terms with a wide array of manufacturers, enabling them to offer competitive pricing without compromising on quality. By fostering strong, ongoing relationships with its suppliers, Beacon can maintain a robust inventory that meets fluctuating market demands. Its revenue stream predominantly flows from sales of these essential building products, while its ancillary services—such as digital and in-person sales consultations—enhance the customer experience. This dual focus on top-notch service and a comprehensive product portfolio has helped Beacon Roofing Supply maintain its sturdy position in the industry, weathering economic cycles with resilient growth strategies.

Show more
Loading

Earnings Calls

2024 Q3
Nov 13, 2024
Show Transcript
Previous
Next
Taysha Gene Therapies Progress in Rett Syndrome Treatment
2024 Q3
Nov 13, 2024

In Q3 2024, Taysha Gene Therapies made significant strides in its TSHA-102 program for Rett syndrome, emphasizing regulatory advancements with the FDA. During this period, they enrolled additional patients in pivotal high-dose trials, showing encouraging safety and efficacy data. Notably, the company anticipates reporting longer-term data from both low and high-dose cohorts in early 2025. As of September 30, 2024, Taysha holds $157.7 million in cash, sufficient to support operations until Q4 2026. The management maintains confidence in TSHA-102’s potential to enhance patient quality of life and aims to expedite the journey toward regulatory approvals.

Show Full Analysis

Management

Mr. Julian G. Francis
President, CEO & Director
No Bio Available
Mr. C. Munroe Best III
President of South Division
No Bio Available
Mr. Jason L. Taylor
President of West Division
No Bio Available
Mr. Jonathan S. Bennett
Executive VP & Chief Commercial Officer
No Bio Available
Mr. Prithvi S. Gandhi
Executive VP & CFO
No Bio Available
Mr. Christopher Carl Nelson
Executive VP & CTO
No Bio Available
Ms. Christine Stroh Reddy
Executive VP, General Counsel & Corporate Secretary
No Bio Available
Ms. Jennifer N. Lewis
VP of Communications & Corporate Social Responsibility
No Bio Available
Mr. Sean M. McDevitt
Executive VP & Chief Human Resources Officer
No Bio Available
Mr. James J. Gosa
President of North Division
No Bio Available

Contacts

Address
VIRGINIA
Herndon
505 Huntmar Park Dr Ste 300
Contacts
+15713233939.0
www.becn.com